Li Guang, Wang Xuefeng, Liu Guobing
Department of Obstetrics and Gynecology, Third Affiliated Hospital of Southern Medical University, Guangzhou, 510515 Guangdong Province, China.
Department of Obstetrics and Gynecology, NanFang Hospital of Southern Medical University, Guangzhou, 510515 Guangdong Province, China.
Biomed Res Int. 2021 Jun 28;2021:5512340. doi: 10.1155/2021/5512340. eCollection 2021.
PLOD2 is overexpressed in diverse tumors and plays a vital role in tumorigenesis. However, the prognostic value of PLOD2 in cervical cancer (CESC) remains unclear.
PLOD2 expression and CESC patients' survival data were collected from the Oncomine, GEPIA, UALCAN, and Kaplan-Meier Plotter databases; immunohistochemistry (IHC) was used to validate the expression of PLOD2 in CESC; Gene Set Enrichment Analysis was performed using the STRING and DAVID databases; and the correlations between PLOD2 and cancer immune infiltrates were investigated using the TIMER and TISIDB databases.
We found that the expression level of PLOD2 was increased in various cancers, and meta-analysis in the Oncomine database revealed that PLOD2 was significantly upregulated in CESC compared to that in normal tissues ( < 0.001). In addition, the high expression of PLOD2 was closely related to poor overall survival (OS) and disease-free survival (DFS) in patients with CESC (OS HR = 1.73, = 0.029; DFS HR = 2.60, = 0.018). Functional annotations indicated that differentially expressed PLOD2 were primarily related to protein digestion and absorption pathways and to the collagen fibril organization process. Immune infiltration analysis showed that PLOD2 was highly correlated with B cells, CD4+ T cells, T helper type 2 (Th2) cells, and eosinophils in CESC.
PLOD2 is positively associated with poor prognosis and might be considered a novel diagnostic and prognostic marker for CESC patients.
PLOD2在多种肿瘤中过表达，并在肿瘤发生中起重要作用。然而，PLOD2在宫颈癌（CESC）中的预后价值仍不清楚。
从Oncomine、GEPIA、UALCAN和Kaplan-Meier Plotter数据库收集PLOD2表达和CESC患者的生存数据；采用免疫组织化学（IHC）验证PLOD2在CESC中的表达；使用STRING和DAVID数据库进行基因集富集分析；并使用TIMER和TISIDB数据库研究PLOD2与癌症免疫浸润之间的相关性。
我们发现PLOD2在各种癌症中的表达水平升高，Oncomine数据库中的荟萃分析显示，与正常组织相比，CESC中PLOD2显著上调（<0.001）。此外，PLOD2的高表达与CESC患者的总生存期（OS）和无病生存期（DFS）差密切相关（OS风险比=1.73，=0.029；DFS风险比=2.60，=0.018）。功能注释表明，差异表达的PLOD2主要与蛋白质消化和吸收途径以及胶原纤维组织过程有关。免疫浸润分析显示，PLOD2与CESC中的B细胞、CD4+T细胞、2型辅助性T细胞（Th2）和嗜酸性粒细胞高度相关。
PLOD2与不良预后呈正相关，可能被视为CESC患者的一种新型诊断和预后标志物。
